Turn Therapeutics Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Turn Therapeutics Inc. (TTRX) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $700.06 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-12
- Turn Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $419.23K, a 788.51% increase year-over-year.
- Turn Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $280.83K, a 266.63% increase year-over-year.
- Turn Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $47.18K.
- Turn Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $76.60K.
- Turn Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $419.25K, a 18.82% increase from fiscal 2024.
- Turn Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $352.83K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|
| 2026-06-30 | $419.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $700.06K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $280.83K 10-Q · filed 2026-05-11 | ||
| 2025-12-31 | $419.25K 10-K · filed 2026-03-31 | ||
| 2025-06-30 | $47.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $123.78K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $76.60K 10-Q · filed 2026-05-11 | ||
| 2024-12-31 | $352.83K 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |